Last update 03 Jan 2025
SHR-A2009
Last update 03 Jan 2025
Overview
Basic Info
Drug Type Antibody drug conjugate (ADC) |
Synonyms SHR A2009, SHR-A2009, SHRA2009 |
Target |
Mechanism HER3 modulators(Receptor tyrosine-protein kinase erbB-3 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (US) |
Login to view timeline
Related
14
Clinical Trials associated with SHR-A2009SHR-A2009对比含铂化疗治疗表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）治疗失败的EGFR突变晚期或转移性非小细胞肺癌的随机对照、开放性、多中心III期研究
[Translation] A randomized, controlled, open-label, multicenter phase III study of SHR-A2009 versus platinum-based chemotherapy in patients with advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations who have failed EGFR tyrosine kinase inhibitor (TKI) therapy
A Randomized, Open-label, Multicenter, Phase III Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer：A Prospective, Open-label, Multicenter, Phase II Trial
100 Clinical Results associated with SHR-A2009
Login to view more data
100 Translational Medicine associated with SHR-A2009
Login to view more data
100 Patents (Medical) associated with SHR-A2009
Login to view more data
100 Deals associated with SHR-A2009
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 3 | CN | 29 Nov 2024 | |
| EGFR-mutated non-small Cell Lung Cancer | Phase 3 | CN | 29 Nov 2024 | |
| Breast Cancer | Phase 2 | CN | 20 Feb 2024 | |
| Solid tumor | Phase 2 | - | - | |
| Advanced cancer | IND Approval | CN | 20 Nov 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT05114759 (ESMO2024) Manual  | Phase 1 | EGFR-mutated non-small Cell Lung Cancer EGFR Mutation | 103 | sdfuwgqrjg(aqgkzldvdg) = 56.3% of 103 pts, with all occurring in ≥5% being hematotoxicities. kiguqsjlqi (wdtteylnqx ) View more | Positive | 14 Sep 2024 | |
SHR-A2009 9.0 mg/kg (Prior PBC treated) | |||||||
Phase 1 | HR-positive/HER2-low Solid Tumors EGFR mutations | 42 | tnsematepr(dnsmsuwaqu) = ddvhnwewtl aamybauzyh (ppuglmfirv ) View more | Positive | 23 Oct 2023 | ||
(1.5 mg/kg) | djpwuuzvaz(rxtuopvcij) = gqczhnnrtr vqdjqocrwp (asknldreop ) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free